Personalis (PSNL) Expected to Announce Quarterly Earnings on Thursday

Personalis (NASDAQ:PSNL) is anticipated to issue its Q4 2025 results before the market opens on Thursday, February 26th. Analysts expect Personalis to post earnings of ($0.31) per share for the quarter. Parties may review the information on the company’s upcoming Q4 2025 earning report for the latest details on the call scheduled for Thursday, February 26, 2026 at 5:00 PM ET.

Personalis Stock Up 0.1%

NASDAQ PSNL opened at $8.29 on Tuesday. Personalis has a twelve month low of $2.83 and a twelve month high of $11.50. The business has a 50-day moving average price of $8.78 and a 200-day moving average price of $7.89. The firm has a market cap of $736.15 million, a price-to-earnings ratio of -9.42 and a beta of 1.98.

Analysts Set New Price Targets

A number of analysts recently weighed in on PSNL shares. Needham & Company LLC increased their price objective on shares of Personalis from $7.00 to $10.00 and gave the stock a “buy” rating in a research report on Wednesday, November 5th. Morgan Stanley boosted their target price on Personalis from $9.00 to $11.00 and gave the stock an “equal weight” rating in a research note on Monday, December 1st. Lake Street Capital reissued a “buy” rating and issued a $11.00 target price on shares of Personalis in a research report on Wednesday, November 5th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Personalis in a research note on Thursday, January 22nd. Finally, Wall Street Zen raised Personalis from a “sell” rating to a “hold” rating in a report on Saturday, January 31st. Six research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Personalis presently has a consensus rating of “Moderate Buy” and a consensus target price of $10.86.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of PSNL. Deutsche Bank AG increased its stake in Personalis by 4.5% in the fourth quarter. Deutsche Bank AG now owns 38,827 shares of the company’s stock valued at $309,000 after purchasing an additional 1,655 shares during the last quarter. Royal Bank of Canada lifted its holdings in shares of Personalis by 3.2% in the 1st quarter. Royal Bank of Canada now owns 78,341 shares of the company’s stock valued at $275,000 after buying an additional 2,395 shares during the period. Howland Capital Management LLC lifted its stake in shares of Personalis by 0.9% in the second quarter. Howland Capital Management LLC now owns 285,308 shares of the company’s stock valued at $1,872,000 after purchasing an additional 2,500 shares during the period. Caitong International Asset Management Co. Ltd boosted its stake in shares of Personalis by 184.8% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 5,536 shares of the company’s stock worth $44,000 after acquiring an additional 3,592 shares in the last quarter. Finally, Intech Investment Management LLC boosted its position in Personalis by 23.4% during the fourth quarter. Intech Investment Management LLC now owns 20,342 shares of the company’s stock worth $162,000 after purchasing an additional 3,851 shares in the last quarter. 61.91% of the stock is owned by institutional investors and hedge funds.

Personalis Company Profile

Personalis, Inc (NASDAQ: PSNL) is a clinical‐stage genomics company that develops and markets advanced next‐generation sequencing (NGS) services and assays designed to accelerate precision medicine. The Company’s core offering is the ImmunoID NeXT™ Platform, which combines comprehensive tumor profiling—including whole exome, transcriptome, and T‐cell receptor sequencing—with proprietary bioinformatics to identify biomarkers and guide immuno‐oncology research. Personalis serves biopharmaceutical companies, academic institutions, and clinical research organizations seeking in‐depth insights into cancer, autoimmune diseases and other complex conditions.

In addition to its flagship ImmunoID NeXT™ Platform, Personalis offers a suite of customizable sequencing assays for biomarker discovery, clinical trial support and companion diagnostic development.